kinesin family member 16BGenealiases: C20orf23 · KISC20ORF · SNX23
Q-omics provides the consensus-scored KIF16B profile across patient tissues and cancer cell-line models. KIF16B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KIF16B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KIF16B RNA expression shows 20,227 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where KIF16B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF16B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF16B survival associations across molecular data types. KIF16B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF16B RNA expression–survival associations across cancer types. High KIF16B expression shows unfavorable associations in BLCA, LGG, LAML and LUSC, but favorable associations in KIRC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for KIF16B RNA expression.
This table summarizes KIF16B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KIF16B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF16B shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LIHC, BRCA and CHOL. The HNSC box plot shows higher KIF16B RNA expression in tumor versus normal tissue (log2 FC = +1.507, t-test p < 0.001).
This table shows molecular features associated with KIF16B in patient tissues and cancer cell lines. In patient samples, KIF16B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF16B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BREAST.
